News | April 19, 2025
Aptar commences clinical study to accelerate FDA approval of SmartTrack
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
New facility is part of Aptar Pharma’s global expansion program
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Subscribe To Our Newsletter & Stay Updated
